Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03643068 · ClinicalTrials.gov registry record · Phase 1
Phase 1A Study of the Safety of KSP/QRH Dimer
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03643068 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 26 participants.
The verdict
NCT03643068, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
To evaluate the safety of orally administered KSP-QRH-E3-IRDye800 (Peptide 919288G), a topically administered Li-Cor IRDye800CW labeled heptapeptide dimer (KSP/QRH Dimer) specific for human epithelial growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR).
Interventions
- DRUG KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg
- DRUG KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-08-22 |
| Est. Completion | 2018-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03643068
The ClinicalTrials.gov registry entry for NCT03643068 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg is the first listed.
NCT03643068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03643068 about?
NCT03643068 is a clinical study titled "Phase 1A Study of the Safety of KSP/QRH Dimer". To evaluate the safety of orally administered KSP-QRH-E3-IRDye800 (Peptide 919288G), a topically administered Li-Cor IRDye800CW labeled heptapeptide dimer (KSP/QRH Dimer) specific for human epithelial growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR).
What is the current status of trial NCT03643068?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2018-08-22. Estimated completion is 2018-10-27.
What interventions are being tested in trial NCT03643068?
The interventions under investigation include: KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg (DRUG), KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg (DRUG).
Who is sponsoring clinical trial NCT03643068?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.